Learning outcomes
By the end of this lesson you should be able to: describe the four pillars of disease-modifying therapy in heart failure with reduced ejection fraction and separate them from the drugs that only relieve symptoms; classify the antiarrhythmics by the Vaughan Williams scheme and name the key agent in each class with its signature toxicity; explain the role of amiodarone, its extraordinary adverse-effect profile and its interactions; list the features of digoxin toxicity and its specific antidote; and outline the drug management of atrial fibrillation with rate control, rhythm control and anticoagulation by the stroke risk score.
Prerequisites
Lessons 7, 8 and 9, plus the cardiac electrophysiology module of the physiology course — the cardiac action potential, ion channels and the phases of depolarisation.
The big idea
The heart failure prescription splits into two shelves. One shelf relieves symptomrs — loop diuretics decongest the patient, digoxin slows the rate — but changes the natural history little. The other shelf is disease-modifying: it blocks the maladaptive neurohormonal cascade (renin-angiotensin-aldosterone and the sympathetic surge) that is the disease progression, and those are the four pillars that reduce mortality. A prescriber who confuses the two shelves gives a diuretic, feels pleased, and stops before reaching the pillars that keep the patient alive.
The four pillars of heart failure
| Pillar | Agents | Symptom or survival | Practical notes |
|---|---|---|---|
| Renin-angiotensin-aldosterone blockade | Ramipril, valsartan, or sacubitril-valsartan (the ARNI) | Survival; also reduces congestion over weeks | Start low, go slow; only titrate the dose once the patient is euvolaemic, and never combine an ACE inhibitor with a neprilysin inhibitor without a washout |
| Beta-blockade | Bisoprolol, carvedilol, nebivolol | Survival; symptom benefit over months | Started when the patient is stable and not overloaded, because in the acute decompensation a beta-blocker can worsen the failure; titrate at two-week intervals |
| Mineralocorticoid receptor antagonism | Spironolactone, eplerenone | Survival | Watch the potassium with the RAS blocker above it; spironolactone's gynaecomastia favours eplerenone |
| SGLT2 inhibition | Dapagliflozin, empagliflozin | Survival, with and without diabetes | Originally glucose-lowering drugs, the benefit in failure is independent of diabetes; diuretic with them and expect genital mycotic infection |
| Loop diuretic | Furosemide, bumetanide | Symptom relief only | The dose is titrated to weight and congestion, and adjusted as the kidney function changes, but it never substitutes for the pillars above |
| Digoxin | Digoxin | Symptom and rate control | Adds little to the mortality pillars; reserved with atrial fibrillation for rate control when the others fail, and toxic easily |
NoteThe order matters as much as the drugs. A newly diagnosed patient starts with a loop diuretic to decongest, then the RAS blocker and the beta-blocker are introduced in small doses at fortnightly intervals, then the mineralocorticoid antagonist and the SGLT2 inhibitor complete the structure. Each up-titration waits on the blood pressure and renal function, because the barriers to the right doses are hypotension, hyperkalaemia and bradycardia, not reluctance.
Digoxin
Digoxin inhibits the sodium-potassium ATPase of the cardiac membrane, so intracellular calcium rises through the sodium-calcium exchanger and the contractile force increases; in the AV node the same inhibition slows conduction through vagal and direct effects, giving a ventricular rate that suits the fibrillating patient. It has a narrow therapeutic index, a long half-life of about thirty-six hours accumulating in renal impairment, and a therapeutic range of roughly 0.5 to 0.8 nanograms per millilitre, above which the vomiting and the arrhythmias begin.
Watch outDigoxin toxicity is the classic viva question. Non-cardiac features are nausea, vomiting, anorexia, xanthopsia (yellow-green vision) and confusion; cardiac features are almost any arrhythmia, including bradycardia and bidirectional ventricular tachycardia. Toxicity is potentiated by hypokalaemia (which any diuretic produces) and by transporters: amiodarone, quinidine and verapamil raise digoxin levels. The antidote is digoxin-specific antibody fragments, given when there are arrhythmias, hyperkalaemia or a level above about ten; hyperkalaemia is itself a marker of severe toxicity.
Antiarrhythmics
| Vaughan Williams class | Channel target | Key agents | Signature toxicity and caveat |
|---|---|---|---|
| Class I — fast sodium channel blockers | Phase 0 depolarisation | Ia quinidine, procainamide; Ib lidocaine, mexiletine; Ic flecainide, propafenone | Flecainide and propafenone must be avoided in structural heart disease, where the trial of their use in post-infarction patients gave excess arrhythmic death |
| Class II — beta-blockers | Sympathetic beta-1 drive | Bisoprolol, metoprolol, atenolol | Bradycardia, exacerbation of asthma, fatigue; the safest and most widely used class |
| Class III — potassium channel blockers | Phase 3 repolarisation | Amiodarone, dronedarone, sotalol | Prolong the QT and risk torsades de pointes; sotalol adds beta-blockade, dronedarone worsens outcomes in permanent atrial fibrillation and in heart failure |
| Class IV — calcium-channel blockers | Nodal calcium current | Verapamil, diltiazem | Avoid in reduced ejection fraction for their negative inotropy, and never with a beta-blocker for their nodal effect |
| Class V — others | Miscellaneous mechanisms | Digoxin (AV node, contractility), adenosine (transient AV block), magnesium | Adenosine causes flushing, chest tightness and bronchospasm, and is contraindicated in asthma as it is given |
Amiodarone deserves its own paragraph because it is effective, heavily used and unique among drugs in the number of organs it can damage. It prolongs the action potential like a class III agent but in fact blocks sodium, calcium and beta channels as well — the pattern of a broad-spectrum antiarrhythmic. It accumulates in fat and the thyroid, taking weeks to reach a steady state and months to leave, and it is a potent cytochrome P450 inhibitor that raises the levels of digoxin, warfarin and statins. Its adverse effects span pulmonary fibrosis (the dose-limiting one), hypothyroidism or hyperthyroidism through its iodine load, corneal microdeposits, hepatotoxicity, slate-grey skin photosensitivity and peripheral neuropathy, so it is started only when the arrhythmia is dangerous or refractory and then with scheduled pulmonary, thyroid, liver and ophthalmic surveillance.
Managing atrial fibrillation
Atrial fibrillation is managed on three fronts simultaneously. Rate control uses a beta-blocker or digoxin (verapamil or diltiazem if a beta-blocker is unsuitable and the ventricular function is preserved). Rhythm control restores and maintains sinus rhythm with amiodarone, or flecainide in a structurally normal heart, and is chosen when the patient is symptomatic, young, or in heart failure. Anticoagulation is decided by the stroke risk score — age, hypertension and other vascular factors, diabetes, and prior stroke or embolism — not by the pulse, and is unaffected by whether the rhythm is regular again. Recent-onset atrial fibrillation undergoing cardioversion needs either a defined period of anticoagulation or exclusion of atrial thrombus first, because restoring coordinated contraction can eject an embolus.
Why does a rate-limited atrial fibrillation still need anticoagulation after a successful rhythm control?
Common mistakes
Watch outStarting a beta-blocker in a patient with acute decompensated, fluid-overloaded heart failure. The failing ventricle at high filling pressure depends on sympathetic drive, and removing it precipitates cardiogenic shock. Beta-blockers are introduced when the patient is stable, euvolaemic and on a ward dose — that is why the first dose is a fraction of the target dose.
Watch outPrescribing flecainide for atrial fibrillation in someone with ischaemic heart disease or reduced ejection fraction. The CAST trial showed excess arrhythmic death, so the class Ic agents are restricted to structurally normal hearts.
Watch outMissing the potassium in digoxin toxicity. A diuretic-driven hypokalaemia potentiates toxicity at a therapeutic digoxin level, and the correct response is to stop the digoxin, replace potassium (carefully in failure) and give the antibody fragments if arrhythmia or hyperkalaemia is present.
Watch outSaying adenosine treats atrial fibrillation. Adenosine transiently blocks the AV node and so terminates or reveals a junctional re-entry tachycardia — it has no role in fibrillation and will not restore sinus rhythm there.
Check your understanding
Which heart failure drugs reduce mortality, and which merely relieve symptoms?
Why does sotalol prolong the QT and risk torsades de pointes?
Which two drugs commonly raise digoxin levels through a transporter, and why does that matter?
Multiple choice
Which drug group in heart failure has a demonstrated mortality benefit?
Which pair of findings is most characteristic of digoxin toxicity?
Which antiarrhythmic is contraindicated in a patient with ischaemic heart disease?
Which drug prolongs the QT interval and risks torsades de pointes in hypokalaemia?
Which drug is used to terminate a junctional re-entry (atrioventricular nodal) tachycardia?